Floatz logo

Talzenna

Fumarate Hydratase Deficient Renal Cell Carcinoma

Memorial Sloan Kettering Cancer CenterPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Fumarate Hydratase Deficient Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
rc48-adc
RenJi Hospital
Phase 2CCC
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Tislelizumab
RenJi Hospital
Phase 2CCC
Bms-907351
Memorial Sloan Kettering Cancer Center
Phase 2CCC
LENVATINIB
RenJi Hospital
Phase 2CCC
Pyrotinib
RenJi Hospital
Phase 2CCC
Avelumab
Memorial Sloan Kettering Cancer Center
Phase 2CCC

Same molecule, other indications

Talzenna is also rated in:

BRCA2-related cancer predispositionDormant
BB
Indicative ·
68 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
Her2-receptor negative breast cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →